Global Guanylate Cyclase-C Agonists Market, By Drug (Trulance, Linzess), Application (Irritable Bowel Syndrome, Chronic Idiopathic Constipation, Others), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Guanylate Cyclase-C Agonists Market Analysis and Size
In recent years, the guanylate cyclase-C agonists market is anticipated to grow rapidly during the forecast period. According to the United Nations' World Population Ageing Highlight 2020 study, the worldwide geriatric population is forecast to rise from 727 million in 2020 to 1.5 billion by 2050, a nearly two-fold increase, while the share of the geriatric population in 2020 was about 9.3%, and is expected to rise to 16% by 2050. Geriatric population are at the high risk of gastrointestinal disorders. This lead to the high demand of guanylate cyclase-C agonists in the healthcare sector.
Data Bridge Market Research analyzes that the guanylate cyclase-C agonists market which was USD 576.03 million in 2022, is likely to reach USD 884.03 million by 2030, and is expected to undergo a CAGR of 5.5% during the forecast period. “Trulance” dominates the drug segment of the guanylate cyclase-C agonists market due to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Drug (Trulance, Linzess), Application (Irritable Bowel Syndrome, Chronic Idiopathic Constipation, Others), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.( Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Boehringer Ingelheim International GmbH. (Germany), Astellas Pharma Inc. (Japan), Allergan (Ireland), Mitsubishi Tanabe Pharma Corporation (Japan), Kyowa Kirin Co., Ltd.(Japan), Liminal BioSciences Inc. (Canada), Avexegen Therapeutics, Inc.(U.S.), AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Constipation associated with irritable bowel syndrome (IBS) and chronic cons1tipation of unclear cause (idiopathic constipation) in adults are treated with guanylate cyclase-C agonists. IBS is characterized by stomach pain or cramps, bloating, and infrequent or difficult bowel movements. Guanylate cyclase-C agonists are prescription pharmaceuticals that can be taken alone or in combination with other drugs.
Global Guanylate Cyclase-C Agonists Market Dynamics
Drivers
- Increasing incidences of gastrointestinal disorders
The rising incidences of gastrointestinal disorders such as chronic idiopathic constipation and irritable bowel syndrome is anticipated to influence the guanylate cyclase-C agonists market's growth. Growing smoking addiction and surging alcohol consumption are some of the causes of gastrointestinal disorders.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of guanylate cyclase-C agonists market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the guanylate cyclase-C agonists market. In addition, high disposable income and sedentary lifestyle of people will result in the expansion of guanylate cyclase-C agonists market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the guanylate cyclase-C agonists market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
- Increasing adoption of targeted therapies
GC-C agonists offer a targeted approach to treating gastrointestinal disorders by specifically activating the GC-C receptor in the intestinal epithelium. This targeted mechanism of action can provide advantages such as improved efficacy and reduced side effects compared to traditional therapies. As the trend towards personalized medicine and targeted therapies continues to grow, GC-C agonists may find increased adoption in the market.
Restraints/Challenges
- Stringent regulatory requirements
Developing and gaining regulatory approval for new pharmaceutical products, including GC-C agonists, can be a complex and time-consuming process. Meeting the stringent regulatory requirements set by health authorities, such as the FDA and EMA, can pose challenges and delays in launching these therapies in the market.
- Limited awareness among healthcare professionals
Despite the potential benefits of GC-C agonists, there may be a lack of awareness and understanding among healthcare professionals about their mechanism of action, efficacy, and appropriate patient selection. This can hinder their adoption and restrict market growth.
This guanylate cyclase-C agonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the guanylate cyclase-C agonists market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In May 2020, Synthetic Biologics announced the initiation of a Phase 2b clinical trial evaluating SYN-004 (a GC-C agonist) for the prevention of Clostridium difficile infection (CDI) in patients hospitalized for a lower respiratory tract infection
- In June 2020, AbbVie announced that it had completed the divestiture of the rights to linaclotide (a GC-C agonist) and the related assets to Nestlé Health Science
- In March 2020, Shionogi announced that the European Medicines Agency (EMA) had accepted its Marketing Authorization Application (MAA) for naldemedine (a PAMORA with GC-C agonist activity) for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
- In February 2020, Ardelyx announced positive results from the Phase 3 AMPLIFY study evaluating tenapanor (a GC-C agonist) for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis
Global Guanylate Cyclase-C Agonists Market Scope
The Guanylate Cyclase-C Agonists market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Trulance
- Linzess
Application
- Irritable Bowel Syndrome
- Chronic Idiopathic Constipation
- Others
Dosage
- Injection
- Tablet
- Others
Route of Administration
- Intravenous
- Oral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Guanylate Cyclase-C Agonists Market Regional Analysis/Insights
The guanylate cyclase-C agonists market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the guanylate cyclase-C agonists market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.
North America is expected to dominate the guanylate cyclase-C agonists market because of the well-established healthcare sector in this region. In addition, growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The guanylate cyclase-C agonists market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Guanylate cyclase-C agonists market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Guanylate cyclase-C agonists market.
Competitive Landscape and Guanylate Cyclase-C Agonists Market Share Analysis
The guanylate cyclase-C agonists market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the guanylate cyclase-C agonists market.
Some of the major players operating in the guanylate cyclase-C agonists market are:
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.( Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Takeda Pharmaceutical Company Limited (Japan)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Astellas Pharma Inc. (Japan)
- Allergan (Ireland)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Kyowa Kirin Co., Ltd.(Japan)
- Liminal BioSciences Inc. (Canada)
- Avexegen Therapeutics, Inc.(U.S.)
- AbbVie Inc. (U.S.)
SKU-